FR2707641B1 - Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique. - Google Patents

Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.

Info

Publication number
FR2707641B1
FR2707641B1 FR9308767A FR9308767A FR2707641B1 FR 2707641 B1 FR2707641 B1 FR 2707641B1 FR 9308767 A FR9308767 A FR 9308767A FR 9308767 A FR9308767 A FR 9308767A FR 2707641 B1 FR2707641 B1 FR 2707641B1
Authority
FR
France
Prior art keywords
imidazol
carboxamide
intermediates
therapy
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9308767A
Other languages
English (en)
Other versions
FR2707641A1 (fr
Inventor
Dodey Pierre
Bondoux Michel
Renaut Patrice
Pruneau Didier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fournier Industrie et Sante SAS
Original Assignee
Fournier Industrie et Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Industrie et Sante SAS filed Critical Fournier Industrie et Sante SAS
Priority to FR9308767A priority Critical patent/FR2707641B1/fr
Publication of FR2707641A1 publication Critical patent/FR2707641A1/fr
Application granted granted Critical
Publication of FR2707641B1 publication Critical patent/FR2707641B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR9308767A 1993-07-16 1993-07-16 Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique. Expired - Fee Related FR2707641B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9308767A FR2707641B1 (fr) 1993-07-16 1993-07-16 Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9308767A FR2707641B1 (fr) 1993-07-16 1993-07-16 Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.

Publications (2)

Publication Number Publication Date
FR2707641A1 FR2707641A1 (fr) 1995-01-20
FR2707641B1 true FR2707641B1 (fr) 1995-08-25

Family

ID=9449319

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9308767A Expired - Fee Related FR2707641B1 (fr) 1993-07-16 1993-07-16 Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.

Country Status (1)

Country Link
FR (1) FR2707641B1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105473548A (zh) * 2013-08-20 2016-04-06 武田药品工业株式会社 作为溶血磷脂酸受体拮抗剂的酰胺衍生物

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2225252T3 (es) * 1999-11-10 2005-03-16 Takeda Chemical Industries, Ltd. Compuestos n-heterociclicos de 5 miembros con actividad hipoglucemica e hipolipidemica.
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2810522A1 (fr) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphes
EP2057160A1 (fr) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3,2-d]pyrimidines utilisees en tant qu'inhibiteurs de dpp-iv pour le traitement du diabete sucre
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR102328772B1 (ko) 2009-11-27 2021-11-19 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA2797310C (fr) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Therapie de combinaison de l'agoniste du recepteur glp-1 et de l'inhibiteur dpp-4
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
KR20190062621A (ko) 2011-07-15 2019-06-05 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (fr) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2015128453A1 (fr) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Utilisation médicale d'un inhibiteur de dpp-4
EP4233840A3 (fr) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinaisons de linagliptine et de metformine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3336326A (en) * 1964-04-16 1967-08-15 Janssen Pharmaceutica Nv Novel imidazole carboxamides
JPH04247081A (ja) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105473548A (zh) * 2013-08-20 2016-04-06 武田药品工业株式会社 作为溶血磷脂酸受体拮抗剂的酰胺衍生物
CN105473548B (zh) * 2013-08-20 2018-03-23 武田药品工业株式会社 作为溶血磷脂酸受体拮抗剂的酰胺衍生物

Also Published As

Publication number Publication date
FR2707641A1 (fr) 1995-01-20

Similar Documents

Publication Publication Date Title
FR2707641B1 (fr) Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.
FR2709754B1 (fr) Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
DZ418A1 (fr) Dérivés de céphalosporine, leur procédé de préparation et leur application thérapeutique.
OA07097A (fr) Nouveaux dérivés d'arylphényléther utiles comme microbicides, procédé pour leur préparation et leur utilisation.
OA09432A (fr) N-aryl-azétidinones, leur procédé de préparation et leur utilisation comme inhibiteurs des élastases.
OA06914A (fr) Procédé de préparation d'iminodiacides substitués.
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
CS29990A3 (en) Racemic or optically active bis-aza-bicyclic compounds, process forpreparing thereof, intermediates and use
FI891338A0 (fi) Parannus menetelmään 2',3'-dideoksi-2',3'-didehydronukleosidien valmistamiseksi
FR2707087B1 (fr) Nouveau procédé de préparation de l'ergothionéine.
KR960009930B1 (en) 5'-phosphonates of 3'-azido-2,'3'-dideoxynucleosides
FR2696744B1 (fr) Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
OA08383A (fr) Procédé de préparation d'urée.
FR2702660B1 (fr) Compositions thérapeutiques stabilisées et leur procédé de préparation.
OA08384A (fr) Procédé de préparation de l'urée.
OA08235A (fr) Composés intermediaires de carbapénem et leur procédé de préparation.
FR2721598B1 (fr) Procédé de préparation de catalyseurs d'ammoxydation.
FR2720070B1 (fr) Procédé de préparation d'alkylpolysiloxanes pontés et alkylpolysiloxanes pontés.
EP0731074A3 (fr) Composés de tétraphénol, procédé pour leur préparation et leur utilisation comme photosensibilisateurs
EP0657438A3 (fr) Procédé pour la préparation d'alkylesulfinylbenzamides et de 1,2-benzoisothiazol-3-ones.
FI945322L (fi) Menetelmä 2',3'-didehydro-2',3'-dideoksinukleosidien laajamittaista valmistusta varten
OA07984A (fr) Procédé stéréocontrolé de préparation d'acetoxyazetidione.
FR2708266B1 (fr) Procédé de préparation d'alcanesulfonamides.
FR2697250B1 (fr) Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique.
FR2695645B1 (fr) Procédé de préparation de polyaminoborazines.

Legal Events

Date Code Title Description
ST Notification of lapse